Your session is about to expire
← Back to Search
Other
NYX-783 for Post-Traumatic Stress Disorder
Verified Trial
Phase 2 & 3
Waitlist Available
Research Sponsored by Aptinyx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Stable allowed medications with no planned changes from 30 days prior to screening through study participation
How tall are you in inches?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study endpoint, up to 10 weeks
Awards & highlights
Study Summary
This trial is testing a new drug, NYX-783, to see if it is safe and effective in treating people with PTSD.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
The study participants can take stable medications without any changes for 30 days before the screening process and during the duration of the study.
Select...
This is not an exclusion criterion. It is a question to gather information about the participant.
Select...
What is your weight in pounds?
Select...
You must agree to use very effective birth control during the study.
Select...
You agree to attend all scheduled visits and follow the study procedures.
Select...
You have been diagnosed with post-traumatic stress disorder (PTSD) according to the DSM-5 criteria.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ study endpoint, up to 10 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study endpoint, up to 10 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
CAPS-5 (Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of' Mental Disorders, 5th edition)
Secondary outcome measures
CGI-S (Clinician Global Impression - Severity)
PGI-S (Patient Global Impression - Severity)
SDS (Sheehan Disability Scale)
Side effects data
From 2020 Phase 2 trial • 160 Patients • NCT040446644%
Headache
4%
Urinary Tract Infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
NYX-783 High Dose (50 mg QD)
Placebo
NYX-783 Low Dose (10 mg QD)
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 50 mg NYX-783 QDExperimental Treatment1 Intervention
50 mg NYX-783 QD
Group II: PlaceboPlacebo Group1 Intervention
Placebo QD
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NYX-783
2019
Completed Phase 2
~160
Find a Location
Who is running the clinical trial?
AptinyxLead Sponsor
8 Previous Clinical Trials
1,213 Total Patients Enrolled
Worldwide Clinical TrialsOTHER
61 Previous Clinical Trials
14,266 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many people are given the opportunity to participate in this research?
"The trial is currently admitting patients at 32 locations across the United States. Originally posted on December 13th, 2021, this study was most recently updated on September 29th, 2022 and 300 participants are needed in total."
Answered by AI
Who else is applying?
What state do they live in?
California
Ohio
Texas
Other
How old are they?
65+
18 - 65
What site did they apply to?
Aptinyx Clinical Site
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
3+
1
Why did patients apply to this trial?
I in my lifetime have tried so many different treatments, weed is the only thing that even touches the symptoms.
PatientReceived 2+ prior treatments
I was in several severe prison riots after doing years in the prison system. I was shot and almost died my life will never be the same.
PatientReceived no prior treatments
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger